Shares of CorMedix Inc. (NYSEAMERICAN:CRMD) were up 18.2% during mid-day trading on Monday . The company traded as high as $0.55 and last traded at $0.52. Approximately 2,678,852 shares traded hands during mid-day trading, an increase of 247% from the average daily volume of 771,174 shares. The stock had previously closed at $0.44.

Separately, HC Wainwright set a $4.00 price objective on shares of CorMedix and gave the company a “buy” rating in a report on Monday, October 16th.

The stock has a market capitalization of $28.59, a price-to-earnings ratio of -0.89 and a beta of 0.18.

In related news, Director Steven W. Lefkowitz acquired 135,416 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was acquired at an average cost of $0.48 per share, for a total transaction of $64,999.68. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Khoso Baluch acquired 104,166 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were bought at an average price of $0.48 per share, with a total value of $49,999.68. Following the completion of the transaction, the chief executive officer now owns 225,373 shares in the company, valued at $108,179.04. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 312,498 shares of company stock valued at $149,999.

A number of hedge funds have recently added to or reduced their stakes in CRMD. Sabby Management LLC acquired a new position in CorMedix during the 2nd quarter worth approximately $1,818,000. Spinnaker Capital LLC acquired a new position in CorMedix during the 4th quarter worth approximately $202,000. Virtu Financial LLC increased its position in CorMedix by 126.4% during the 4th quarter. Virtu Financial LLC now owns 226,748 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 126,610 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in CorMedix by 3.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock worth $518,000 after purchasing an additional 35,148 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “CorMedix (CRMD) Trading Up 18.2%” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://theolympiareport.com/2018/02/12/cormedix-crmd-trading-up-18-2.html.

CorMedix Company Profile

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.